References
- Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol 2011; 29: 235-71. doi: 10.1146/annurev-immunol-031210-101324
- Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science 2011; 331: 1565-70. doi: 10.1126/science.1203486
- Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 1988; 319: 1676-80. doi: 10.1056/nejm198812223192527
- Sadelain M, Rivière I, Riddell S. Therapeutic T cell engineering. Nature 2017; 545: 423-31. doi: 10.1038/nature22395
- Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013; 368: 1509-18. doi: 10.1056/NEJMoa1215134
- Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 2018; 378: 439-48. doi: 10.1056/nejmoa1709866
- Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 2015; 385: 517-28. doi: 10.1016/S0140-6736(14)61403-3
- Schuster SJ, Svoboda J, Chong EA, Nasta SD, Mato AR, Anak Ö, et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N Engl J Med 2017; 28: 2545-54. doi: 10.1056/NEJMoa1708566
- Sommermeyer D, Hudecek M, Kosasih PL, Gogishvili T, Maloney DG, Turtle CJ, et al. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia 2016; 30: 492-500. doi: 10.1038/leu.2015.247
- Brentjens RJ, Rivière I, Park JH, Davila ML, Wang X, Stefanski J, et al Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011; 118: 4817-28. doi: 10.1182/blood-2011-04-348540
- Porter DL, Levine BL, Kalos M, Bagg A, June CH, Levine BL, et al. Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365: 725-33. doi: 10.1056/nejmoa1103849
- Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 2017; 377: 2531-44. doi: 10.1056/nejmoa1707447
- Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 2019; 380: 45-56. doi: 10.1056/nejmoa1804980
- Abramson JS, McGree B, Sarah Noyes N, Sean Plummer B, Curtis Wong B, Chen YB, et al. Anti-CD19 CAR T cells in CNS diffuse large-B-cell lymphoma. N Engl J Med 2017; 377: 783-4. doi: 10.1056/NEJMc1704610
- Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011; 3: 95ra73. doi: 10.1126/scitranslmed.3002842
- Kochenderfer JN, Wilson WH, Janik JE, Dudley ME, Stetler-Stevenson M, Feldman SA, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood 2010; 116: 4099-102. doi: 10.1182/blood-2010-04-281931
- Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy – assessment and management of toxicities. Nat Rev Clin Oncol 2017; 15: 47-62. doi: 10.1038/nrclinonc.2017.148
- Brudno JN, Kochenderfer JN. Recent advances in CAR T-cell toxicity: mechanisms, manifestations and management. Blood Rev 2019; 34: 45-55. doi: 10.1016/j.blre.2018.11.002
- Liu E, Marin D, Banerjee P, MacApinlac HA, Thompson P, Basar R, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med 2020; 382: 545-53. doi: 10.1056/nejmoa1910607
- Klichinsky M, Ruella M, Shestova O, Lu XM, Best A, Zeeman M, et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat Biotechnol 2020; 38: 947-53. doi: 10.1038/s41587-020-0462-y
- Ellebrecht CT, Bhoj VG, Nace A, Choi EJ, Mao X, Cho MJ, et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science 2016; 353: 179-84. doi: 10.1126/science.aaf6756
- Mackensen A, Müller F, Mougiakakos D, Böltz S, Wilhelm A, Aigner M, et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med 2022; 28: 2124-32. doi: 10.1038/s41591-022-02017-5
- Mougiakakos D, Krönke G, Völkl S, Kretschmann S, Aigner M, Kharboutli S, et al. CD19-Targeted CAR T cells in refractory systemic lupus erythematosus. N Engl J Med 2021; 385: 567-9. doi: 10.1056/nejmc2107725
- Maldini CR, Gayout K, Leibman RS, Dopkin DL, Mills JP, Shan X, et al. HIV-resistant and HIV-specific CAR-modified CD4+ T cells mitigate HIV disease progression and confer CD4+ T cell help in vivo. Mol Ther 2020; 28: 1-15. doi: 10.1016/j.ymthe.2020.05.012
- Maldini CR, Claiborne DT, Okawa K, Chen T, Dopkin DL, Shan X, et al. Dual CD4-based CAR T cells with distinct costimulatory domains mitigate HIV pathogenesis in vivo. Nat Med 2020; 26: 1776-87. doi: 10.1038/s41591-020-1039-5
- Amor C, Feucht J, Leibold J, Ho YJ, Zhu C, Alonso-Curbelo D, et al. Senolytic CAR T cells reverse senescence-associated pathologies. Nature 2020; 583: 127-32. doi: 10.1038/s41586-020-2403-9
- Aghajanian H, Kimura T, Rurik JG, Hancock AS, Leibowitz MS, Li L, et al. Targeting cardiac fibrosis with engineered T cells. Nature 2019; 573: 430-3. doi: 10.1038/s41586-019-1546-z
- Kalos M, June CH. Adoptive T Cell Transfer for cancer immunotherapy in the era of synthetic biology. Immunity 2013; 39: 49-60. doi: 10.1016/j. immuni.2013.07.002
- June CH, O ’connor RS, Kawalekar OU, Ghassemi S, Milone MC, O’Connor RS, et al. CAR T cell immunotherapy for human cancer. Science 2018; 1365: 1361-5. doi: 10.1126/science.aar6711
- Kuwana Y, Asakura Y, Utsunomiya N, Nakanishi M, Arata Y, Itoh S, et al. Expression of chimeric receptor composed of immunoglobulin-derived V resions and T-cell receptor-derived C regions. Biochem Biophys Res Commun 1987; 149: 960-8. doi: 10.1016/0006-291X(87)90502-X
- Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or ζ subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A 1993; 90: 720-4. doi: 10.1073/pnas.90.2.720
- Brocker T, Karjalainen K. Signals through T cell receptor-ζ chain alone are insufficient to prime resting T lymphocytes. J Exp Med 1995; 181: 1653-9. doi: 10.1084/jem.181.5.1653
- Ghorashian S, Kramer AM, Onuoha S, Wright G, Bartram J, Richardson R, et al Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR. Nat Med 2019; 25: 1408-14. doi: 10.1038/s41591-019-0549-5
- Singh N, Frey N V., Engels B, Barrett DM, Shestova O, Ravikumar P, et al. Antigen-independent activation enhances the efficacy of 4-1BB-costimulated CD22 CAR T cells. Nat Med 2021; 27: 842-50. doi: 10.1038/s41591-021-01326-5
- Posey AD, Schwab RD, Boesteanu AC, Steentoft C, Mandel U, Engels B, et al. Engineered CAR T cells targeting the cancer-associated Tn-glycoform of the membrane mucin MUC1 control adenocarcinoma. Immunity 2016; 44: 1444-54. doi: 10.1016/j.immuni.2016.05.014
- Harris DT, Kranz DM. Adoptive T Cell therapies: a comparison of T cell receptors and chimeric antigen receptors. Trends Pharmacol Sci 2015; 37: 220-30. doi: 10.1016/j.tips.2015.11.004
- Bashor CJ, Hilton IB, Bandukwala H, Smith DM, Veiseh O. Engineering the next generation of cell-based therapeutics. Nat Rev Drug Discov 2022; 21: 655-75. doi: 10.1038/s41573-022-00476-6
- Mullard A. FDA approves second BCMA-targeted CAR-T cell therapy. Nat Rev Drug Discov 2022; 21: 249. doi: 10.1038/d41573-022-00048-8
- MacKay M, Afshinnekoo E, Rub J, Hassan C, Khunte M, Baskaran N, et al. The therapeutic landscape for cells engineered with chimeric antigen receptors. Nat Biotechnol 2020; 38: 233-44. doi: 10.1038/s41587-019-0329-2
- Johnson LA, June CH. Driving gene-engineered T cell immunotherapy of cancer. Cell Res 2016; 27: 38-58. doi: 10.1038/cr.2016.154
- Elazar A, Chandler NJ, Davey AS, Weinstein JY, Nguyen J V., Trenker R, et al. De novo-designed transmembrane domains tune engineered receptor functions. Elife 2022; 11: 1-29. doi: 10.7554/eLife.75660
- Muller YD, Nguyen DP, Ferreira LMR, Ho P, Raffin C, Valencia RVB, et al. The CD28-transmembrane domain mediates chimeric antigen receptor heter-odimerization with CD28. Front Immunol 2021; 12: 639818. doi: 10.3389/fimmu.2021.639818
- Kershaw MH, Westwood J a, Parker LL, Wang G, Eshhar Z, Mavroukakis S a, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 2006; 12: 6106-15. doi: 10.1158/1078-0432.CCR-06-1183
- Krause A, Guo HF, Latouche JB, Tan C, Cheung NK V., Sadelain M. Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J Exp Med 1998; 188: 619-26. doi: 10.1084/jem.188.4.619
- Maher J, Brentjens RJ, Gunset G, Rivière I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ/CD28 receptor. Nat Biotechnol 2002; 20: 70-5. doi: 10.1038/nbt0102-70
- Hombach A, Wieczarkowiecz A, Marquardt T, Heuser C, Usai L, Pohl C, et al. Tumor-specific T cell activation by recombinant immunoreceptors: CD3ζ signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3ζ signaling receptor molecule. J Immunol 2001; 167: 6123-31. doi: 10.4049/jimmunol.167.11.6123
- Kawalekar OU, O’Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD, et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T Cells. Immunity 2016; 44: 380-90. doi: 10.1016/j.immuni.2016.01.021
- Bachy E, Le Gouill S, Di Blasi R, Sesques P, Manson G, Cartron G, et al. A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma. Nat Med 2022; 28: 2145-54. doi: 10.1038/s41591-022-01969-y
- Song DG, Ye Q, Poussin M, Harms GM, Figini M, Powell DJ. CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo. Blood 2012; 119: 696-706. doi: 10.1182/blood-2011-03-344275
- Guedan S, Chen X, Madar A, Carpenito C, McGettigan SE, Frigault MJ, et al. ICOS-based chimeric antigen receptors program bipolar TH 17/ TH1 cells. Blood 2014; 124: 1070-80. doi: 10.1182/blood-2013-10-535245
- Hombach AA, Heiders J, Foppe M, Chmielewski M, Abken H. OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4+ T cells. Oncoimmunology 2012; 1: 458-66. doi: 10.4161/onci.19855
- Ramos CA, Rouce R, Robertson CS, Reyna A, Narala N, Vyas G, et al. In vivo fate and activity of second- versus third-generation CD19-specific CAR-T cells in B cell Non-Hodgkin’s lymphomas. Mol Ther 2018; 26: 2727-37. doi: 10.1016/j.ymthe.2018.09.009
- Wijewarnasuriya D, Bebernitz C, Lopez AV, Rafiq S, Brentjens RJ. Excessive costimulation leads to dysfunction of adoptively transferred T cells. Cancer Immunol Res 2020; 18: 732-42. doi: 10.1158/2326-6066.CIR-19-0908
- Melenhorst JJ, Chen GM, Wang M, Porter DL, Chen C, Collins MKA, et al. Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. Nature 2022; 602: 503-9. doi: 10.1038/s41586-021-04390-6
- Gordon KS, Kyung T, Perez CR, Holec P V., Ramos A, Zhang AQ, et al. Screening for CD19-specific chimaeric antigen receptors with enhanced signalling via a barcoded library of intracellular domains. Nat Biomed Eng 2022; 6: 855-66. doi: 10.1038/s41551-022-00896-0
- Love PE, Hayes SM. ITAM-mediated signaling by the T-cell antigen receptor. Cold Spring Harb Perspect Biol 2010; 2: 1-11. doi: 10.1101/cshperspect. a002485
- Wu W, Zhou Q, Masubuchi T, Shi X, Li H, Xu X, et al. Multiple signaling roles of CD3ε and its application in CAR-T cell therapy. Cell 2020; 182: 855-871. e23. doi: 10.1016/j.cell.2020.07.018
- Feucht J, Sun J, Eyquem J, Ho YJ, Zhao Z, Leibold J, et al. Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nat Med 2019; 25: 82-8. doi: 10.1038/s41591-018-0290-5
- Mansilla-Soto J, Eyquem J, Haubner S, Hamieh M, Feucht J, Paillon N, et al. HLA-independent T cell receptors for targeting tumors with low antigen density. Nat Med 2022; 28: 345-52. doi: 10.1038/s41591-021-01621-1
- Zhang L, Morgan RA, Beane JD, Zheng Z, Dudley ME, Kassim SH, et al. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clin Cancer Res 2015; 21: 2278-88. doi: 10.1158/1078-0432. CCR-14-2085
- Hu B, Ren J, Luo Y, Scholler J, Zhao Y, June CH, et al. CAR T cells secreting IL18 augment antitumor immunity and increase T cell proliferation and costimulation. Cell Rep 2017; 20: 3025-33. doi: 10.1016/j.celrep.2017.09.002
- Kunert A, Chmielewski M, Wijers R, Berrevoets C, Abken H, Debets R. Intratumoral production of IL18, but not IL12, by TCR-engineered T cells is non-toxic and counteracts immune evasion of solid tumors. Oncoimmunology 2017; 7: 1-12. doi: 10.1080/2162402X.2017.1378842
- Chmielewski M, Abken H. CAR T cells releasing IL-18 convert to T-Bet high FoxO1 low effectors that exhibit augmented activity against advanced solid tumors. Cell Rep 2017; 21: 3205-19. doi: 10.1016/j.celrep.2017.11.063
- Zimmermann K, Kuehle J, Dragon AC, Galla M, Kloth C, Rudek LS, et al. Design and characterization of an “all-in-one” lentiviral vector system combining constitutive anti-gd2 car expression and inducible cytokines. Cancers 2020; 12: 1-22. doi: 10.3390/cancers12020375
- Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, van Leeuwen DG, Drakes DJ, et al. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol 2018; 36: 847-56. doi: 10.1038/nbt.4195
- Yin Y, Boesteanu AC, Binder ZA, Xu C, Reid RA, Rodriguez JL, et al. Checkpoint blockade reverses anergy in IL-13Rα2 humanized scFv-based CAR T cells to treat murine and canine gliomas. Mol Ther Oncolytics 2018; 11: 20-38. doi: 10.1016/j.omto.2018.08.002
- Kuhn NF, Purdon TJ, van Leeuwen DG, Lopez A V., Curran KJ, Daniyan AF, et al. CD40 ligand-modified chimeric antigen receptor T cells enhance antitumor function by eliciting an endogenous antitumor response. Cancer Cell 2019; 35: 473-88. doi: 10.1016/j.ccell.2019.02.006
- Yamamoto TN, Lee P-HH, Vodnala SK, Gurusamy D, Kishton RJ, Yu Z, et al. T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy. J Clin Invest 2019; 129: 1551-65. doi: 10.1172/JCI121491
- Oda SK, Anderson KG, Ravikumar P, Bonson P, Garcia NM, Jenkins CM, et al. A Fas-4-1BB fusion protein converts a death to a pro-survival signal and enhances T cell therapy. J Exp Med 2020; 217: 1-16. doi: 10.1084/jem.20191166
- Jin C, Ma J, Ramachandran M, Yu D, Essand M. CAR T cells expressing a bacterial virulence factor trigger potent bystander antitumour responses in solid cancers. Nat Biomed Eng 2022; 6: 830-41. doi: 10.1038/s41551-022-00875-5
- Narayan V, Barber-Rotenberg JS, Jung IY, Lacey SF, Rech AJ, Davis MM, et al. PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med 2022; 28: 724-34. doi: 10.1038/s41591-022-01726-1
- Roth TL, Li PJ, Blaeschke F, Nies JF, Apathy R, Mowery C, et al. Pooled knockin targeting for genome engineering of cellular immunotherapies. Cell 2020; 181: 728-744.e21. doi: 10.1016/j.cell.2020.03.039
- Roybal KT, Williams JZ, Morsut L, Walker WJ, Mcnally KA, Lim WA. Engineering T cells with customized therapeutic article engineering T cells with customized therapeutic response programs using synthetic notch receptors. Cell 2016; 167: 419-32. doi: 10.1016/j.cell.2016.09.011
- Rodriguez-garcia A, Lynn RC, Poussin M, Eiva MA, Shaw LC, Connor RSO, et al. CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy. Nat Commun 2021; 12: 877. doi: 10.1038/s41467-021-20893-2
- Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med 2018; 24: 563-71. doi: 10.1038/s41591-018-0010-1
- Good CR, Aznar MA, Kuramitsu S, Samareh P, Agarwal S, Donahue G, et al. An NK-like CAR T cell transition in CAR T cell dysfunction. Cell 2021; 184: 6081-6100.e26. doi: 10.1016/j.cell.2021.11.016
- Weber EW, Parker KR, Sotillo E, Lynn RC, Anbunathan H, Lattin J, et al. Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling. Science 2021; 372: eaba1786. doi: 10.1126/science. aba 1786
- Lynn RC, Weber EW, Sotillo E, Gennert D, Xu P, Good Z, et al. c-Jun overexpression in CAR T cells induces exhaustion resistance. Nature 2019; 576: 293-300. doi: 10.1038/s41586-019-1805-z
- Seo H, González-Avalos E, Zhang W, Ramchandani P, Yang C, Lio CWJ, et al BATF and IRF4 cooperate to counter exhaustion in tumor-infiltrating CAR T cells. Nat Immunol 2021; 22: 983-95. doi: 10.1038/s41590-021-00964-8
- Deng Q, Han G, Puebla-Osorio N, Ma MCJ, Strati P, Chasen B, et al. Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nat Med 2020; 26: 1878-87. doi: 10.1038/s41591-020-1061-7
- Adachi K, Kano Y, Nagai T, Okuyama N, Sakoda Y, Tamada K. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat Biotechnol 2018; 36: 346-51. doi: 10.1038/nbt.4086
- Shum T, Omer B, Tashiro H, Kruse RL, Wagner DL, Parikh K, et al. Constitutive signaling from an engineered IL7 receptor promotes durable tumor elimination by tumor-redirected T cells. Cancer Discov 2017; 7: 1238-47. doi: 10.1158/2159-8290.CD-17-0538
- Alizadeh D, Wong RA, Yang X, Wang D, Pecoraro JR, Kuo CF, et al. IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype. Cancer Immunol Res 2019; 7: 759-72. doi: 10.1158/2326-6066.CIR-18-0466
- Kalbasi A, Siurala M, Su LL, Tariveranmoshabad M, Picton LK, Ravikumar P, et al. Potentiating adoptive cell therapy using synthetic IL-9 receptors. Nature 2022; 607: 360-5. doi: 10.1038/s41586-022-04801-2
- Legut M, Gajic Z, Guarino M, Daniloski Z, Rahman JA, Xue X, et al. A genome-scale screen for synthetic drivers of T cell proliferation. Nature 2022; 603: 728-35. doi: 10.1038/s41586-022-04494-7
- Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of t cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010; 18: 843-51. doi: 10.1038/mt.2010.24
- Kim MY, Yu KR, Kenderian SS, Ruella M, Chen S, Shin TH, et al. Genetic inactivation of CD33 in hematopoietic stem cells to enable CAR T cell immunotherapy for acute myeloid leukemia. Cell 2018; 173: 1439-1453.e19. doi: 10.1016/j.cell.2018.05.013
- Qazi MA, Vora P, Venugopal C, Sidhu SS, Moffat J, Swanton C, et al. Intratumoral heterogeneity: pathways to treatment resistance and relapse in human glioblastoma. Ann Oncol 2017; 28: 1448-56. doi: 10.1093/annonc/mdx169
- Ruella M, Maus M V. Catch me if you can: leukemia escape after CD19-directed T cell immunotherapies. Comput Struct Biotechnol J 2016; 14: 357-62. doi: 10.1016/j.csbj.2016.09.003
- Cordoba S, Onuoha S, Thomas S, Pignataro DS, Hough R, Ghorashian S, et al. CAR T cells with dual targeting of CD19 and CD22 in pediatric and young adult patients with relapsed or refractory B cell acute lymphoblastic leukemia: a phase 1 trial. Nat Med 2021; 27: 1797-805. doi: 10.1038/s41591-021-01497-1
- Fry TJ, Shah NN, Orentas RJ, Stetler-Stevenson M, Yuan CM, Ramakrishna S, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med 2018; 24: 20-8. doi: 10.1038/nm.4441
- Spiegel JY, Patel S, Muffly L, Hossain NM, Oak J, Baird JH, et al. CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial. Nat Med 2021; 27: 1419-31. doi: 10.1038/s41591-021-01436-0
- Minutolo NG, Sharma P, Poussin M, Shaw LC, Brown DP, Hollander EE, et al. Quantitative control of gene-engineered T-cell activity through the covalent attachment of targeting ligands to a universal immune receptor. J Am Chem Soc 2020; 142: 6554-68. doi: 10.1021/jacs.9b11622
- Cho JH, Collins JJ, Wong WW. Universal chimeric antigen receptors for multiplexed and logical control of T cell responses. Cell 2018; 173: 1426-1438. e11. doi: 10.1016/j.cell.2018.03.038
- Tran E, Robbins PF, Lu Y-C, Prickett TD, Gartner JJ, Jia L, et al T-cell transfer therapy targeting mutant KRAS in cancer. N Engl J Med 2016; 375: 2255-62. doi: 10.1056/NEJMoa1609279
- Chheda ZS, Kohanbash G, Okada K, Jahan N, Sidney J, Pecoraro M, et al. Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy. J Exp Med 2018; 215: 141-57. doi: 10.1084/jem.20171046
- Leidner R, Sanjuan Silva N, Huang H, Sprott D, Zheng C, Shih Y-P, et al. Neoantigen T-cell receptor gene therapy in pancreatic cancer. N Engl J Med 2022; 386: 2112-9. doi: 10.1056/nejmoa2119662
- Bear AS, Blanchard T, Cesare J, Ford MJ, Richman LP, Xu C, et al. Biochemical and functional characterization of mutant KRAS epitopes validates this on-coprotein for immunological targeting. Nat Commun 2021; 12: 1-16. doi: 10.1038/s41467-021-24562-2
- Yarmarkovich M, Marshall QF, Warrington JM, Premaratne R, Farrel A, Groff D, et al. Cross-HLA targeting of intracellular oncoproteins with peptide-centric CARs. Nature 2021; 599: 477-84. doi: 10.1038/s41586-021-04061-6
- Ruella M, Xu J, Barrett DM, Fraietta JA, Reich TJ, Ambrose DE, et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med 2018; 24: 1499-503. doi: 10.1038/s41591-018-0201-9
- Ghassemi S, Durgin JS, Nunez-Cruz S, Patel J, Leferovich J, Pinzone M, et al. Rapid manufacturing of non-activated potent CAR T cells. Nat Biomed Eng 2022; 6: 118-28. doi: 10.1038/s41551-021-00842-6
- Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest 2016; 126: 2123-38. doi: 10.1172/JCI85309
- Arcangeli S, Bove C, Mezzanotte C, Camisa B, Falcone L, Manfredi F, et al. CAR T cell manufacturing from naive/stem memory T lymphocytes enhances antitumor responses while curtailing cytokine release syndrome. J Clin Invest 2022; 132: e150807. doi: 10.1172/JCI150807
- Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov 2020; 19: 185-99. doi: 10.1038/s41573-019-0051-2
- Qasim W, Zhan H, Samarasinghe S, Adams S, Amrolia P, Stafford S, et al. Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells. Sci Transl Med 2017; 9: 1-9. doi: 10.1126/scitranslmed. aaj2013
- Lu Y, Xue J, Deng T, Zhou X, Yu K, Deng L, et al. Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer. Nat Med 2020; 26: 732-40. doi: 10.1038/s41591-020-0840-5
- Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, et al. CRISPR-engineered T cells in patients with refractory cancer. Science 2020; 367: 1-12. doi: 10.1126/science.aba7365
- Eyquem J, Mansilla-Soto J, Giavridis T, Van Der Stegen SJC, Hamieh M, Cunanan KM, et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature 2017; 543: 113-7. doi: 10.1038/nature21405
- Dai X, Park JJ, Du Y, Kim HR, Wang G, Errami Y, et al. One-step generation of modular CAR-T cells with AAV-Cpf1. Nat Methods 2019; 16: 247-54. doi: 10.1038/s41592-019-0329-7
- Roth TL, Puig-Saus C, Yu R, Shifrut E, Carnevale J, Li PJ, et al. Reprogramming human T cell function and specificity with non-viral genome targeting. Nature 2018; 559: 405-9. doi: 10.1038/s41586-018-0326-5
- Zhang J, Hu Y, Yang J, Li W, Zhang M, Wang Q, et al. Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL. Nature 2022; 609: 369-74. doi: 10.1038/s41586-022-05140-y
- Rurik JG, Tombácz I, Yadegari A, Fernández POM, Shewale S V, Li L, et al. CAR T cells produced in vivo to treat cardiac injury. Science 2022; 96: 91-6. doi: 10.1126/science.abm0594
- June CH, Warshauer JT, Bluestone JA. Is autoimmunity the Achilles’ heel of cancer immunotherapy? Nat Med 2017; 23: 540-7. doi: 10.1038/nm.4321
- Singh N, Hofmann TJ, Gershenson Z, Levine BL, Grupp SA, Teachey DT, et al. Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function. Cytotherapy 2017; 19: 867-80. doi: 10.1016/j. jcyt.2017.04.001
- Parker KR, Migliorini D, Perkey E, Yost KE, Bhaduri A, Bagga P, et al. Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies. Cell 2020; 183: 126-142.e17. doi: 10.1016/j.cell.2020.08.022
- Wu C-Y, Roybal KT, Puchner EM, Onuffer J, Lim WA. Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science 2015; 350: aab4077. doi: 10.1126/science.aab4077
- Juillerat A, Marechal A, Filhol JM, Valton J, Duclert A, Poirot L, et al. Design of chimeric antigen receptors with integrated controllable transient functions. Sci Rep 2016; 6: 1-7. doi: 10.1038/srep18950
- Giordano-Attianese G, Gainza P, Gray-Gaillard E, Cribioli E, Shui S, Kim S, et al. A computationally designed chimeric antigen receptor provides a small-molecule safety switch for T-cell therapy. Nat Biotechnol 2020; 38: 426-32. doi: 10.1038/s41587-019-0403-9
- Hoyos V, Savoldo B, Quintarelli C, Mahendravada A, Zhang M, Vera J, et al. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 2010; 24: 1160-70. doi: 10.1038/leu.2010.75
- Paszkiewicz PJ, Fräßle SP, Srivastava S, Sommermeyer D, Hudecek M, Drexler I, et al. Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia. J Clin Invest 2016; 126: 4262-72. doi: 10.1172/JCI84813
- Roybal KT, Rupp LJ, Morsut L, Walker WJ, McNally KA, Park JS, et al. Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell 2016; 164: 1-10. doi: 10.1016/j.cell.2016.01.011
- Tran E, Ahmadzadeh M, Lu YC, Gros A, Turcotte S, Robbins PF, et al. Immunogenicity of somatic mutations in human gastrointestinal cancers. Science 2015; 350: 1387-90. doi: 10.1126/science.aad1253
- Zacharakis N, Chinnasamy H, Black M, Xu H, Lu YC, Zheng Z, et al. Immune recognition of somatic mutations leading to complete durable regression in metastatic breast cancer. Nat Med 2018; 1: 724-30. doi: 10.1038/s41591-018-0040-8